RadNet's DeepHealth Unveils AI-Powered Innovations in Medical Imaging at RSNA 2024

RadNet's Wholly-Owned Subsidiary, DeepHealth, Launches New AI-powered Informatics and SmartTechnology™ Innovations at #RSNA2024 By Investing.com

To extend and scale these solutions, DeepHealth has established strategic ecosystem collaborations with health industry-leading OEMs GE HealthCare and Siemens Healthineers, leading AI infrastructure solutions company CARPL.ai, leading Enterprise Imaging solutions provider TeraRecon, and cloud technology leader Google (NASDAQ:GOOGL). LOS ANGELES and SOMERVILLE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet , Inc. (Nasdaq: NASDAQ:RDNT), has launched new AI-powered solutions at RSNA 2024. These solutions enable breakthroughs in imaging-based diagnosis, population health screening programs, and efficient large-scale imaging operations. Moreover, DeepHealth launches SmartTechnology™ solutions that integrate advanced AI and informatics with imaging systems for more efficient, patient-centric workflows. This comprehensive portfolio, anchored on the cloud-native DeepHealth OS, is designed to improve operational efficiency, enhance clinical confidence, while elevating the experiences of patients and care teams. DeepHealth has established strategic collaborations with industry leaders in healthcare, medical imaging, AI, and cloud platforms to continuously innovate solutions, business models, and new care paradigms with the aim of empowering breakthroughs in care by unlocking the value of imaging. FDA 510(k) pending. DeepHealth's latest innovations harness the power of AI to address pressing clinical and operational challenges in complex, high-volume care settings. These innovations include: At DeepHealth, we are leveraging the transformative power of AI to create SmartTechnology™ by seamlessly integrating advanced AI with systems and into workflows, said Kees Wesdorp, President and CEO of RadNet's Digital Health division. DeepHealth has created a cohesive novel portfolio of AI-powered solutions that improve operational efficiency and clinical confidence across the end-to-end radiology workflow. With radiology's increasing role in population health, we uniquely augment and integrate our core radiology informatics solutions and diagnostic AI tools for breast, lung, prostate, and brain health to enable population screening programs at scale. At RSNA 2024, we're presenting next-generation solutions powered by DeepHealth OS and showing how we can build the infrastructure and ecosystem needed for AI adoption to enable better clinical outcomes and operational efficiency. DeepHealth OS " Transforming Clinical Workflows with Scalable AI The radiology workflow is complex and tends to be siloed, with many different stakeholders using disconnected devices for various tasks and managing disparate data sources throughout the patient care journey. DeepHealth OS unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for every stakeholder in the radiology continuum, including patients, operations, referring physicians, technologists, and radiologists. The workspaces are tailored to the needs of stakeholders, with personalized experiences, secure access to a unified patient view, and provide AI-powered task-specific applications. This approach enhances clinical and operational efficiency and improves outcomes and patient experience by ensuring all health actions are well-coordinated, and the right data is available at the right time. In addition, DeepHealth OS, with its modular, scalable, and cloud-native architecture ensures seamless interoperability with existing hardware and software. Diagnostic Suite - Integrating Key AI and Advanced Visualization Capabilities Diagnostic Suite harnesses the cloud-native capabilities of DeepHealth OS to deliver a cutting-edge evolution of the traditional Picture Archiving and Communication System (PACS). This enterprise imaging solution is designed to be interoperable, efficient, and highly scalable, offering a unified diagnostic workspace with an image management layer purpose-built for AI orchestration and inferencing. It features a fast streaming viewer accessible from anywhere, which will be enhanced with advanced visualization tools from TeraRecon for an elevated user experience across complex studies. The Diagnostic Suite also embeds and will extend CARPL.ai's advanced AI infrastructure for dynamic monitoring and continuous optimization of clinical AI performance and safety, aiming to create a unique AI control system to accelerate AI adoption. Diagnostic Suite already has its first customer with national full-service radiology provider ONRAD, which was announced earlier. TechLive - Empowering Operational Oversight and Seamless Remote Collaboration TechLive aims to revolutionize clinical and radiology practices with a remote centralized command center that allows technologists and other users to remotely access imaging devices (including MR, CT, and Ultrasound) across multiple locations, supporting real-time scanning, support, training, monitoring, and protocol standardization from a single workspace. The solution is designed to facilitate seamless collaboration and resource scaling in complex imaging environments without geographic constraints. The remote scanning solution is consistent with recently updated accreditation guidelines on safe remote scanning operations. The solution has already shown the potential to have significant impact in clinical practice and will be demonstrated at the DeepHealth booth. SmartTechnnology - Enhancing Workflows and Clinical Confidence DeepHealth unveils SmartTechnology, a groundbreaking product category that seamlessly integrates AI-powered informatics with advanced imaging systems. This innovative solution bridges the gap between patient imaging at the modality level (e.g., image acquisition with a mammography system) and diagnostic interpretation (e.g., breast lesion detection), which is traditionally performed on separate devices and at different points in time. By unifying these processes, SmartTechnology enables more efficient, faster, patient-centric workflows, potentially redefining the future of healthcare delivery. The leading example in this new category, SmartMammo™, integrates AI with mammography systems to improve the accuracy of lesion detection, classify tissue density, and elevate generalists' detection rates to those of specialists. Combined with GE HealthCare's patient-centric Senographe Pristina™, SmartMammo is capable of returning lesion scoring within five minutes of scanning, enabling faster and more reliable breast cancer screening. Such workflows can enable same-day diagnosis and immediate results communication to patients. SmartMammo is also compatible with Hologic (NASDAQ:HOLX)'s DBT mammography systems. SmartMammo will be demonstrated at the DeepHealth and GE HealthCare booths. SmartSonography™, another SmartTechnology initiative, is aimed at enhancing ultrasound-based diagnostics. In collaboration with Siemens Healthineers, by combining their Acuson Sequoia with DeepHealth's SmartSonography solution, the two companies aim to enable real-time remote imaging support, improve diagnostic precision, and address workforce challenges. Together, DeepHealth and Siemens Healthineers intend to pave the way for smarter, more efficient, and accessible ultrasound care. SmartSonography will be demonstrated at the DeepHealth and Siemens Healthineers booths. Kim et al. Impact of a Categorical AI System for Digital Breast Tomosynthesis on Breast Cancer Interpretation by Both General Radiologists and Breast Imaging Specialists. Radiol Artif Intell. 2024. doi: 10.1148/ryai.230137. Together, DeepHealth and Siemens Healthineers intend to pave the way for smarter, more efficient, and accessible ultrasound care. SmartSonography will be demonstrated at the DeepHealth and Siemens Healthineers booths. Further Updates to DeepHealth's Broader Portfolio Beyond the new introductions, DeepHealth will also demonstrate updates to its broader enterprise imaging and population health portfolio. This includes new features and updates to its breast, lung, prostate, and brain AI solutions and advances in Radiology Information System (RIS). Elements of DeepHealth's portfolio are already delivering meaningful impact for patients and healthcare providers around the world, with over 800 clinical sites and more than 3,000 radiologists leveraging its current RIS, PACS, and AI solutions to deliver better care. DeepHealth's end-to-end clinical AI solutions are also powering large scale diagnostic and screening programs for breast cancer in the US and for lung cancer in Europe. At RSNA 2024, DeepHealth's complete portfolio of solutions is presented at Booth no. 1340, South Hall, Level 3 at McCormick (NYSE:MKC) Place in Chicago. About RadNet, Inc. RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 399 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 10,000 employees. For more information, visit http://www.radnet.com. About DeepHealth DeepHealth is a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for all companies within RadNet's Digital Health division. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (i.e., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth and Kheiron breast AI and Quantib prostate and brain AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth's portfolio is a cloud-native operating system - DeepHealth OS - that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth's human-centered, intuitive technology aims to push the boundaries of what's possible in healthcare. https://deephealth.com/ Not all products are cleared for use in all markets. Forward Looking Statement This press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements regarding the capabilities of RadNet, GE Healthcare, HOPPR, TeraRecon and DeepHealth's informatics, hardware and software product portfolios and the collaboration's impact on radiology practices and healthcare workflow, are expressions of our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: anticipate, intend, plan, goal, seek, believe, project, estimate, expect, strategy, future, likely, may, should, will and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements.

RadNet's Wholly-Owned Subsidiary, DeepHealth, Launches New AI-powered Informatics and SmartTechnology™ Innovations at #RSNA2024 - RadNet (NASDAQ:RDNT)

At RSNA 2024, DeepHealth launches new AI-powered informatics and SmartTechnology™ solutions powered by DeepHealth OS, its pioneering cloud-native operating system. These solutions, deployed on the secure, scalable, and interoperable OS, address clinical and operational challenges across the imaging value chain.DeepHealth's AI-powered informatics portfolio features the newly introduced Diagnostic Suite™ and TechLive™1, integrated workspaces for radiologists and technologists. In addition, portfolio updates in Radiology Information System (RIS) and clinical AI are showcased. DeepHealth introduces SmartTechnology™, an innovative category of solutions that integrate advanced AI and informatics with imaging systems to enable novel integrated workflows between image scanning and interpretation. The first two solutions in this category, SmartMammo™ with GE HealthCare's mammography systems and SmartSonography™ with Siemens Healthineers ultrasound systems, are poised to have a transformative impact on patient care. To extend and scale these solutions, DeepHealth has established strategic ecosystem collaborations with health industry-leading OEMs GE HealthCare and Siemens Healthineers, leading AI infrastructure solutions company CARPL.ai, leading Enterprise Imaging solutions provider TeraRecon, and cloud technology leader Google. LOS ANGELES and SOMERVILLE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. RDNT, has launched new AI-powered solutions at RSNA 2024. These solutions enable breakthroughs in imaging-based diagnosis, population health screening programs, and efficient large-scale imaging operations. Moreover, DeepHealth launches SmartTechnology™ solutions that integrate advanced AI and informatics with imaging systems for more efficient, patient-centric workflows. This comprehensive portfolio, anchored on the cloud-native DeepHealth OS, is designed to improve operational efficiency, enhance clinical confidence, while elevating the experiences of patients and care teams. DeepHealth has established strategic collaborations with industry leaders in healthcare, medical imaging, AI, and cloud platforms to continuously innovate solutions, business models, and new care paradigms with the aim of empowering breakthroughs in care by unlocking the value of imaging. 1 FDA 510(k) pending. DeepHealth's latest innovations harness the power of AI to address pressing clinical and operational challenges in complex, high-volume care settings. These innovations include: DeepHealth OS - a cloud-native, AI-powered operating system that unifies data across clinical and operational workflows and is at the core of DeepHealth's portfolio.Diagnostic Suite™ - a modernized version of a traditional Picture Archiving and Communication System (PACS). It is a comprehensive interpretation and image management solution that provides a unified diagnostic workspace with a fast streaming viewer, smart reporting features, and advanced image management capabilities.TechLive™1 - an AI-powered, multi-modality remote-scanning platform designed to enable collaboration and knowledge sharing across an imaging fleet in real-time.SmartTechnology™ - solutions that integrate AI-powered informatics with imaging systems to drive AI adoption, productivity, and better clinical outcomes through innovative industry collaborations with leading imaging OEMs. "At DeepHealth, we are leveraging the transformative power of AI to create SmartTechnology™ by seamlessly integrating advanced AI with systems and into workflows," said Kees Wesdorp, President and CEO of RadNet's Digital Health division. "DeepHealth has created a cohesive novel portfolio of AI-powered solutions that improve operational efficiency and clinical confidence across the end-to-end radiology workflow. With radiology's increasing role in population health, we uniquely augment and integrate our core radiology informatics solutions and diagnostic AI tools for breast, lung, prostate, and brain health to enable population screening programs at scale. At RSNA 2024, we're presenting next-generation solutions powered by DeepHealth OS and showing how we can build the infrastructure and ecosystem needed for AI adoption to enable better clinical outcomes and operational efficiency." DeepHealth OS - Transforming Clinical Workflows with Scalable AI The radiology workflow is complex and tends to be siloed, with many different stakeholders using disconnected devices for various tasks and managing disparate data sources throughout the patient care journey. DeepHealth OS unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for every stakeholder in the radiology continuum, including patients, operations, referring physicians, technologists, and radiologists. The workspaces are tailored to the needs of stakeholders, with personalized experiences, secure access to a unified patient view, and provide AI-powered task-specific applications. This approach enhances clinical and operational efficiency and improves outcomes and patient experience by ensuring all health actions are well-coordinated, and the right data is available at the right time. In addition, DeepHealth OS, with its modular, scalable, and cloud-native architecture ensures seamless interoperability with existing hardware and software. Diagnostic Suite - Integrating Key AI and Advanced Visualization Capabilities Diagnostic Suite harnesses the cloud-native capabilities of DeepHealth OS to deliver a cutting-edge evolution of the traditional Picture Archiving and Communication System (PACS). This enterprise imaging solution is designed to be interoperable, efficient, and highly scalable, offering a unified diagnostic workspace with an image management layer purpose-built for AI orchestration and inferencing. It features a fast streaming viewer accessible from anywhere, which will be enhanced with advanced visualization tools from TeraRecon for an elevated user experience across complex studies. The Diagnostic Suite also embeds and will extend CARPL.ai's advanced AI infrastructure for dynamic monitoring and continuous optimization of clinical AI performance and safety, aiming to create a unique AI control system to accelerate AI adoption. Diagnostic Suite already has its first customer with national full-service radiology provider ONRAD, which was announced earlier. TechLive - Empowering Operational Oversight and Seamless Remote Collaboration TechLive aims to revolutionize clinical and radiology practices with a remote centralized command center that allows technologists and other users to remotely access imaging devices (including MR, CT, and Ultrasound) across multiple locations, supporting real-time scanning, support, training, monitoring, and protocol standardization from a single workspace. The solution is designed to facilitate seamless collaboration and resource scaling in complex imaging environments without geographic constraints. The remote scanning solution is consistent with recently updated accreditation guidelines on safe remote scanning operations. The solution has already shown the potential to have significant impact in clinical practice and will be demonstrated at the DeepHealth booth. SmartTechnnology - Enhancing Workflows and Clinical Confidence DeepHealth unveils SmartTechnology, a groundbreaking product category that seamlessly integrates AI-powered informatics with advanced imaging systems. This innovative solution bridges the gap between patient imaging at the modality level (e.g., image acquisition with a mammography system) and diagnostic interpretation (e.g., breast lesion detection), which is traditionally performed on separate devices and at different points in time. By unifying these processes, SmartTechnology enables more efficient, faster, patient-centric workflows, potentially redefining the future of healthcare delivery. The leading example in this new category, SmartMammo™, integrates AI with mammography systems to improve the accuracy of lesion detection, classify tissue density, and elevate generalists' detection rates to those of specialists2. Combined with GE HealthCare's patient-centric Senographe Pristina™, SmartMammo is capable of returning lesion scoring within five minutes of scanning, enabling faster and more reliable breast cancer screening. Such workflows can enable same-day diagnosis and immediate results communication to patients. SmartMammo is also compatible with Hologic's DBT mammography systems. SmartMammo will be demonstrated at the DeepHealth and GE HealthCare booths. SmartSonography™, another SmartTechnology initiative, is aimed at enhancing ultrasound-based diagnostics. In collaboration with Siemens Healthineers, by combining their Acuson Sequoia with DeepHealth's SmartSonography solution, the two companies aim to enable real-time remote imaging support, improve diagnostic precision, and address workforce challenges. Together, DeepHealth and Siemens Healthineers intend to pave the way for smarter, more efficient, and accessible ultrasound care. SmartSonography will be demonstrated at the DeepHealth and Siemens Healthineers booths. 2 Kim et al. Impact of a Categorical AI System for Digital Breast Tomosynthesis on Breast Cancer Interpretation by Both General Radiologists and Breast Imaging Specialists. Radiol Artif Intell. 2024. doi: 10.1148/ryai.230137. Together, DeepHealth and Siemens Healthineers intend to pave the way for smarter, more efficient, and accessible ultrasound care. SmartSonography will be demonstrated at the DeepHealth and Siemens Healthineers booths. Further Updates to DeepHealth's Broader Portfolio Beyond the new introductions, DeepHealth will also demonstrate updates to its broader enterprise imaging and population health portfolio. This includes new features and updates to its breast, lung, prostate, and brain AI solutions and advances in Radiology Information System (RIS). Elements of DeepHealth's portfolio are already delivering meaningful impact for patients and healthcare providers around the world, with over 800 clinical sites and more than 3,000 radiologists leveraging its current RIS, PACS, and AI solutions to deliver better care. DeepHealth's end-to-end clinical AI solutions are also powering large scale diagnostic and screening programs for breast cancer in the US and for lung cancer in Europe. At RSNA 2024, DeepHealth's complete portfolio of solutions3 is presented at Booth no. 1340, South Hall, Level 3 at McCormick Place in Chicago. About RadNet, Inc. RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 399 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 10,000 employees. For more information, visit http://www.radnet.com. About DeepHealth DeepHealth is a wholly-owned subsidiary of RadNet, Inc. RDNT and serves as the umbrella brand for all companies within RadNet's Digital Health division. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (i.e., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth and Kheiron breast AI and Quantib prostate and brain AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth's portfolio is a cloud-native operating system - DeepHealth OS - that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth's human-centered, intuitive technology aims to push the boundaries of what's possible in healthcare. https://deephealth.com/ 3 Not all products are cleared for use in all markets. Forward Looking Statement This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements regarding the capabilities of RadNet, GE Healthcare, HOPPR, TeraRecon and DeepHealth's informatics, hardware and software product portfolios and the collaboration's impact on radiology practices and healthcare workflow, are expressions of our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements. For media inquiries, reach out to: DeepHealth Andra Axente Communications Director Phone: +31 614 440971 Email: andra.axente@deephealth.com RadNet, Inc. Mark Stolper Executive Vice President and Chief Financial Officer 310-445-2800 Market News and Data brought to you by Benzinga APIs

Siemens Healthineers and RadNet's Wholly-Owned Subsidiary, DeepHealth, to Collaborate Around Elevating Ultrasound Workflows with AI-Powered SmartTechnology™ - RadNet (NASDAQ:RDNT)

Siemens Healthineers and DeepHealth have signed a letter of intent to create AI-powered SmartTechnology™ to improve patient experience and operational efficiency in ultrasound. The collaboration aims to facilitate remote operations, collaboration, and enhanced interpretation capabilities for increased diagnostic accuracy and consistency by combining Siemens Healthineers' Acuson Sequoia with RadNet's DeepHealth SmartSonography™.A live demonstration of the technology will be held Tuesday, December 3, 10:00 AM - 10:30 AM CT at Booth #2529, South Hall, Level 3 at RSNA 2024, Chicago, IL. LOS ANGELES and SOMERVILLE, Mass., Dec. 01, 2024 (GLOBE NEWSWIRE) -- Siemens Healthineers and DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. RDNT, today announced a strategic collaboration aimed at transforming ultrasound operations through the implementation of SmartTechnology™ by embedding AI-powered health informatics within workflows and imaging hardware. The collaboration will combine Siemens Healthineers' Acuson Sequoia ultrasound system, RadNet's expertise in high-volume outpatient care, and DeepHealth's SmartSonography™ solution powered by the cloud-native DeepHealth OS to tackle workflow and workforce challenges for enhanced operational efficiency and better patient experience. High-volume ultrasound care settings face significant challenges, including workforce shortages, operator limitations and fatigue, and variability in image acquisition quality -- factors that can impede timely and accurate diagnoses while contributing to unnecessary examinations. To tackle these challenges, a remote collaboration and image acquisition command center will enable experienced technologists to oversee image acquisition across multiple locations. In addition, enhanced enterprise viewer capabilities are intended to enable radiologists to review video capture of exams alongside standard ultrasound static images for a more comprehensive assessment, potentially improving diagnostic accuracy and reducing unnecessary rescans. This approach could significantly enhance access to higher-quality care and reduce patient recall rates. "Ultrasound has long been plagued with challenges related to lack of standardization and variability among users, and this is only compounded with the global workforce shortage," said Ajay Gannerkote, global head of ultrasound for Siemens Healthineers. "Siemens Healthineers focuses on practical AI, to make ultrasound smarter, faster, easier and more accessible. By collaborating with DeepHealth we can develop smarter ultrasound solutions that help improve productivity and access to high-quality imaging for more people." "We are excited to collaborate with Siemens Healthineers to redefine the landscape of ultrasound diagnostics through SmartTechnology™," said Kees Wesdorp, President and CEO of RadNet's Digital Health segment. "By integrating our AI-powered SmartSonography™ solution with Siemens Healthineers' industry-leading ultrasound systems, we aim to enhance operational efficiency and empower healthcare professionals to deliver more accurate and timely patient care. This collaboration exemplifies our commitment to leveraging advanced technology to empower breakthroughs in care through imaging for both providers and patients." SmartSonography™ is designed to include: 1) a remote-acquisition platform that will enable real-time scanning, assistance, training, monitoring, and protocol standardization across an imaging fleet from a single interface, intending to facilitate seamless collaboration and resource scaling in complex healthcare environments, efficient patient management and enhanced clinical confidence; 2) a cloud-native enterprise viewer accessible from anywhere that will combine essential Picture Archive and Communication Systems (PACS) functionality with cloud-native technology for fast image streaming and seamless access to data with the aim to increase diagnostic accuracy and consistency. Siemens Healthineers harnesses AI to make ultrasound exams faster, smarter and more accessible to healthcare settings worldwide, including underserved areas. Siemens Healthineers has recently refreshed its Ultrasound portfolio and has a fleet of systems that are designed with AI and future development in mind. The company is focused on cardiology, including leadership in interventional cardiology, and adiology/general imaging with unique offerings for liver, breast, vascular and MSK. On December 1, 2024, the Acuson Sequoia 3.5 was introduced with a first-of-its-kind AI Abdomen feature that automatically labels and measures organs in milliseconds to improve standardization, and brings new capabilities in breast and MSK imaging. Together, Siemens Healthineers and DeepHealth are committed to exploring next-generation ultrasound solutions that would enhance the diagnostic process, dramatically reduce scan time and operator-dependant variability, and enable better patient care. For more information, visit the Siemens Healthineers (#2529) and DeepHealth (#1340) booths at the Radiological Society of North America 2024 Annual Meeting, which will be held between 1 and 5 December in Chicago, U.S.A. A live demonstration of the technology will be held Tuesday, December 3, 10AM - 10:30AM CT at Booth #2529, South Hall, Level 3. About Siemens Healthineers Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2024, which ended on September 30, 2024, Siemens Healthineers had approximately 72,000 employees worldwide and generated revenue of around €22.4 billion. Further information is available at www.siemens-healthineers.com. About RadNet, Inc. RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 399 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 10,000 employees. For more information, visit http://www.radnet.com. About DeepHealth DeepHealth is a wholly-owned subsidiary of RadNet, Inc. RDNT and serves as the umbrella brand for all companies within RadNet's Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (i.e., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth and Kheiron breast AI and Quantib prostate and brain AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth's portfolio is a cloud-native operating system - DeepHealth OS - that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth's human-centered, intuitive technology aims to push the boundaries of what's possible in healthcare. https://deephealth.com/ Forward Looking Statement This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements regarding the capabilities of RadNet, Siemens Healthineers, and DeepHealth's informatics, hardware and software product portfolios and the collaboration's impact on radiology practices and healthcare workflow, are expressions of our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements. For media inquiries, reach out to: Siemens Healthineers Bailey Allen Media Relations Manager Phone: +1 610.545.9327 Email: bailey.allen@siemens-healthineers.com DeepHealth Andra Axente Communications Director Phone: +31 614 440971 Email: andra.axente@deephealth.com RadNet, Inc. Mark Stolper Executive Vice President and Chief Financial Officer 310-445-2800 Market News and Data brought to you by Benzinga APIs

Siemens Healthineers and RadNet's Wholly-Owned Subsidiary, DeepHealth, to Collaborate Around Elevating Ultrasound Workflows with AI-Powered SmartTechnology™

and , (GLOBE NEWSWIRE) -- Siemens Healthineers and , a global leader in AI-powered health informatics and a wholly-owned subsidiary of (Nasdaq: RDNT), today announced a strategic collaboration aimed at transforming ultrasound operations through the implementation of SmartTechnology™ by embedding AI-powered health informatics within workflows and imaging hardware. The collaboration will combine Siemens Healthineers' Acuson Sequoia ultrasound system, RadNet's expertise in high-volume outpatient care, and DeepHealth's SmartSonography™ solution powered by the cloud-native DeepHealth OS to tackle workflow and workforce challenges for enhanced operational efficiency and better patient experience. High-volume ultrasound care settings face significant challenges, including workforce shortages, operator limitations and fatigue, and variability in image acquisition quality -- factors that can impede timely and accurate diagnoses while contributing to unnecessary examinations. To tackle these challenges, a remote collaboration and image acquisition command center will enable experienced technologists to oversee image acquisition across multiple locations. In addition, enhanced enterprise viewer capabilities are intended to enable radiologists to review video capture of exams alongside standard ultrasound static images for a more comprehensive assessment, potentially improving diagnostic accuracy and reducing unnecessary rescans. This approach could significantly enhance access to higher-quality care and reduce patient recall rates. "Ultrasound has long been plagued with challenges related to lack of standardization and variability among users, and this is only compounded with the global workforce shortage," said Ajay Gannerkote, global head of ultrasound for Siemens Healthineers. "Siemens Healthineers focuses on practical AI, to make ultrasound smarter, faster, easier and more accessible. By collaborating with DeepHealth we can develop smarter ultrasound solutions that help improve productivity and access to high-quality imaging for more people." "We are excited to collaborate with Siemens Healthineers to redefine the landscape of ultrasound diagnostics through SmartTechnology™," said , President and CEO of RadNet's segment. "By integrating our AI-powered SmartSonography™ solution with Siemens Healthineers' industry-leading ultrasound systems, we aim to enhance operational efficiency and empower healthcare professionals to deliver more accurate and timely patient care. This collaboration exemplifies our commitment to leveraging advanced technology to empower breakthroughs in care through imaging for both providers and patients." SmartSonography™ is designed to include: 1) a remote-acquisition platform that will enable real-time scanning, assistance, training, monitoring, and protocol standardization across an imaging fleet from a single interface, intending to facilitate seamless collaboration and resource scaling in complex healthcare environments, efficient patient management and enhanced clinical confidence; 2) a cloud-native enterprise viewer accessible from anywhere that will combine essential Picture Archive and Communication Systems (PACS) functionality with cloud-native technology for fast image streaming and seamless access to data with the aim to increase diagnostic accuracy and consistency. Siemens Healthineers harnesses AI to make ultrasound exams faster, smarter and more accessible to healthcare settings worldwide, including underserved areas. Siemens Healthineers has recently refreshed its Ultrasound portfolio and has a fleet of systems that are designed with AI and future development in mind. The company is focused on cardiology, including leadership in interventional cardiology, and adiology/general imaging with unique offerings for liver, breast, vascular and MSK. On , the Acuson Sequoia 3.5 was introduced with a first-of-its-kind AI Abdomen feature that automatically labels and measures organs in milliseconds to improve standardization, and brings new capabilities in breast and MSK imaging. Together, Siemens Healthineers and DeepHealth are committed to exploring next-generation ultrasound solutions that would enhance the diagnostic process, dramatically reduce scan time and operator-dependant variability, and enable better patient care. For more information, visit the Siemens Healthineers (#2529) and DeepHealth (#1340) booths at the Radiological Society of 2024 Annual Meeting, which will be held between 1 and 5 December in A live demonstration of the technology will be held , - at Booth #2529, South Hall, Level 3. About Siemens Healthineers Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in , and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2024, which ended on , Siemens Healthineers had approximately 72,000 employees worldwide and generated revenue of around €22.4 billion. Further information is available at www.siemens-healthineers.com. About is the leading national provider of freestanding, fixed-site diagnostic imaging services in based on the number of locations and annual imaging revenue. has a network of 399 owned and/or operated outpatient imaging centers. RadNet's markets include , , , , , , and . In addition, provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, has a total of over 10,000 employees. For more information, visit http://www.radnet.com. About DeepHealth DeepHealth is a wholly-owned subsidiary of (NASDAQ: RDNT) and serves as the umbrella brand for all companies within segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (i.e., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth and Kheiron breast AI and Quantib prostate and brain AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth's portfolio is a cloud-native operating system - DeepHealth OS - that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth's human-centered, intuitive technology aims to push the boundaries of what's possible in healthcare. https://deephealth.com/ Forward Looking Statement This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements regarding the capabilities of , Siemens Healthineers, and DeepHealth's informatics, hardware and software product portfolios and the collaboration's impact on radiology practices and healthcare workflow, are expressions of our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements.

Siemens Healthineers and RadNet's Wholly-Owned Subsidiary, DeepHealth, to Collaborate Around Elevating Ultrasound Workflows with AI-Powered SmartTechnology™ By Investing.com

LOS ANGELES and SOMERVILLE, Mass., Dec. 01, 2024 (GLOBE NEWSWIRE) -- Siemens Healthineers and DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), today announced a strategic collaboration aimed at transforming ultrasound operations through the implementation of SmartTechnology™ by embedding AI-powered health informatics within workflows and imaging hardware. The collaboration will combine Siemens Healthineers' Acuson Sequoia ultrasound system, RadNet's expertise in high-volume outpatient care, and DeepHealth's SmartSonography™ solution powered by the cloud-native DeepHealth OS to tackle workflow and workforce challenges for enhanced operational efficiency and better patient experience. High-volume ultrasound care settings face significant challenges, including workforce shortages, operator limitations and fatigue, and variability in image acquisition quality"factors that can impede timely and accurate diagnoses while contributing to unnecessary examinations. To tackle these challenges, a remote collaboration and image acquisition command center will enable experienced technologists to oversee image acquisition across multiple locations. In addition, enhanced enterprise viewer capabilities are intended to enable radiologists to review video capture of exams alongside standard ultrasound static images for a more comprehensive assessment, potentially improving diagnostic accuracy and reducing unnecessary rescans. This approach could significantly enhance access to higher-quality care and reduce patient recall rates. Ultrasound has long been plagued with challenges related to lack of standardization and variability among users, and this is only compounded with the global workforce shortage, said Ajay Gannerkote, global head of ultrasound for Siemens Healthineers. Siemens Healthineers focuses on practical AI, to make ultrasound smarter, faster, easier and more accessible. By collaborating with DeepHealth we can develop smarter ultrasound solutions that help improve productivity and access to high-quality imaging for more people. "We are excited to collaborate with Siemens Healthineers to redefine the landscape of ultrasound diagnostics through SmartTechnology™, said Kees Wesdorp, President and CEO of RadNet's Digital Health segment. "By integrating our AI-powered SmartSonography™ solution with Siemens Healthineers' industry-leading ultrasound systems, we aim to enhance operational efficiency and empower healthcare professionals to deliver more accurate and timely patient care. This collaboration exemplifies our commitment to leveraging advanced technology to empower breakthroughs in care through imaging for both providers and patients." SmartSonography™ is designed to include: 1) a remote-acquisition platform that will enable real-time scanning, assistance, training, monitoring, and protocol standardization across an imaging fleet from a single interface, intending to facilitate seamless collaboration and resource scaling in complex healthcare environments, efficient patient management and enhanced clinical confidence; 2) a cloud-native enterprise viewer accessible from anywhere that will combine essential Picture Archive and Communication Systems (PACS) functionality with cloud-native technology for fast image streaming and seamless access to data with the aim to increase diagnostic accuracy and consistency. Siemens Healthineers harnesses AI to make ultrasound exams faster, smarter and more accessible to healthcare settings worldwide, including underserved areas. Siemens Healthineers has recently refreshed its Ultrasound portfolio and has a fleet of systems that are designed with AI and future development in mind. The company is focused on cardiology, including leadership in interventional cardiology, and adiology/general imaging with unique offerings for liver, breast, vascular and MSK. On December 1, 2024, the Acuson Sequoia 3.5 was introduced with a first-of-its-kind AI Abdomen feature that automatically labels and measures organs in milliseconds to improve standardization, and brings new capabilities in breast and MSK imaging. Together, Siemens Healthineers and DeepHealth are committed to exploring next-generation ultrasound solutions that would enhance the diagnostic process, dramatically reduce scan time and operator-dependant variability, and enable better patient care. For more information, visit the Siemens Healthineers (#2529) and DeepHealth (#1340) booths at the Radiological Society of North America 2024 Annual Meeting, which will be held between 1 and 5 December in Chicago, U.S.A. A live demonstration of the technology will be held Tuesday, December 3, 10AM " 10:30AM CT at Booth #2529, South Hall, Level 3. About Siemens Healthineers Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG (ETR:SHLG), listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2024, which ended on September 30, 2024, Siemens Healthineers had approximately 72,000 employees worldwide and generated revenue of around €22.4 billion. Further information is available at www.siemens-healthineers.com. About RadNet, Inc. RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 399 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 10,000 employees. For more information, visit http://www.radnet.com. About DeepHealth DeepHealth is a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for all companies within RadNet's Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (i.e., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth and Kheiron breast AI and Quantib prostate and brain AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth's portfolio is a cloud-native operating system - DeepHealth OS - that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth's human-centered, intuitive technology aims to push the boundaries of what's possible in healthcare. https://deephealth.com/ Forward Looking Statement This press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements regarding the capabilities of RadNet, Siemens Healthineers, and DeepHealth's informatics, hardware and software product portfolios and the collaboration's impact on radiology practices and healthcare workflow, are expressions of our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: anticipate, intend, plan, goal, seek, believe, project, estimate, expect, strategy, future, likely, may, should, will and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements.

RadNet's Wholly-Owned Subsidiary, DeepHealth, to Use CARPL.ai's Platform to Develop a New AI Control System for Clinical AI Performance and Safety - RadNet (NASDAQ:RDNT)

DeepHealth and CARPL.ai have established a strategic collaboration to create a unique Artificial Intelligence (AI) control system for image interpretation to ensure AI scalability, performance monitoring, and safety, with the aim to accelerate the adoption of AI. DeepHealth currently monitors the performance of DeepHealth's SmartMammo™ AI-powered solution for breast cancer detection at RadNet. Through the collaboration, the two companies aim to expand, productize and scale this control system across more applications to other customers. Furthermore, DeepHealth will embed CARPL.ai's cutting-edge AI orchestration capabilities that enable easy selection, implementation, and monitoring of appropriate AI models within DeepHealth's cloud-native operating system, DeepHealth OS. LOS ANGELES and SOMERVILLE, Mass., Dec. 01, 2024 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. RDNT, today announced a strategic collaboration with CARPL.ai, a leading AI orchestration company that enables radiologists to access, assess, and integrate radiology AI solutions in their workflows. DeepHealth will use CARPL.ai's technology to develop an AI control system that can be commercialized and will be designed to monitor and optimize imaging AI performance for improved clinical outcomes, operational efficiency, and accelerated adoption of AI in radiology. AI monitoring is crucial to ensure reliable, accurate, and unbiased performance. The two companies will collaborate on a new closed-loop AI feedback system that will continually monitor AI model accuracy and relevance in clinical settings. The system will automate the measurement and monitoring of performance and safety metrics such as specificity, sensitivity, data- and model drift. "Establishing a robust AI infrastructure with monitoring tools is key for safe, effective, and scalable AI adoption in radiology. While the current landscape is marked by an overwhelming array of AI-enabled point solutions, the future involves running multiple AI models, even for a single use case. DeepHealth's partnership with CARPL.ai addresses this very need by creating a unique environment to dynamically run a combination of models and monitor performance and then continuously optimize the best models for specific tasks," said Sham Sokka, PhD, Chief Operating and Technology Officer, DeepHealth. The partnership will also combine CARPL.ai's AI marketplace and orchestration platform, which offers a simplified process for selecting, implementing, and monitoring third-party FDA-cleared AI models, with DeepHealth's cloud-native operating system, DeepHealth OS, which unifies data across the clinical and operational workflows. These platforms will be integrated and extended to monitor real-world workflows on an ongoing basis. The aim is to enable radiologists to access performant and safe AI interpretation tools deeply integrated in their workflows. "We are very excited to partner with DeepHealth to harness the transformative potential of AI within the radiology care continuum, particularly through workflow automation and clinical assistance. This new AI infrastructure is set to fundamentally redefine radiology by making AI an integral component of the system," said Dr. Vidur Mahajan, CEO of CARPL.ai. "Monitoring AI performance is essential to ensure the reliability and accuracy of AI applications over time, and our technology enables real-time performance monitoring of both their accuracy and consistency for safe and effective use of AI in clinical practice." For more information, visit the DeepHealth (#1340) and CARPL.ai (#5733) booths at the Radiological Society of North America 2024 Annual Meeting. About RadNet, Inc. RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 399 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 10,000 employees. For more information, visit http://www.radnet.com. About DeepHealth DeepHealth is a wholly-owned subsidiary of RadNet, Inc. RDNT and serves as the umbrella brand for all companies within RadNet's Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (i.e., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth and Kheiron breast AI and Quantib prostate and brain AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth's portfolio is a cloud-native operating system - DeepHealth OS - that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth's human-centered, intuitive technology aims to push the boundaries of what's possible in healthcare. https://deephealth.com/ About CARPL.ai CARPL.ai is a vendor-neutral Artificial Intelligence (AI) platform that allows radiologists to access, assess, and integrate radiology AI solutions in their clinical practice. CARPL provides a single user interface, a single data channel, and a single procurement channel for the testing, deployment, and monitoring of AI solutions in clinical radiology workflows. We are the world's largest radiology AI marketplace offering 140+ applications from 60+ AI vendors. For more information, visit https://carpl.ai/. Forward Looking Statement This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements regarding the capabilities of RadNet, CARPL.ai, and DeepHealth's informatics, hardware and software product portfolios and the collaboration's impact on radiology practices and healthcare workflow, are expressions of our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements. For media inquiries, reach out to: DeepHealth Andra Axente Communications Director Phone: +31 614 440971 Email: andra.axente@deephealth.com RadNet, Inc. Mark Stolper Executive Vice President and Chief Financial Officer 310-445-2800 CARPL.ai Shruti Singhal Director - Marketing +919811189074 Market News and Data brought to you by Benzinga APIs

RadNet's Wholly-Owned Subsidiary, DeepHealth, to Use CARPL.ai's Platform to Develop a New AI Control System for Clinical AI Performance and Safety

and , (GLOBE NEWSWIRE) -- , a global leader in AI-powered health informatics and a wholly-owned subsidiary of (NASDAQ: RDNT), today announced a strategic collaboration with CARPL.ai, a leading AI orchestration company that enables radiologists to access, assess, and integrate radiology AI solutions in their workflows. DeepHealth will use CARPL.ai's technology to develop an AI control system that can be commercialized and will be designed to monitor and optimize imaging AI performance for improved clinical outcomes, operational efficiency, and accelerated adoption of AI in radiology. AI monitoring is crucial to ensure reliable, accurate, and unbiased performance. The two companies will collaborate on a new closed-loop AI feedback system that will continually monitor AI model accuracy and relevance in clinical settings. The system will automate the measurement and monitoring of performance and safety metrics such as specificity, sensitivity, data- and model drift. "Establishing a robust AI infrastructure with monitoring tools is key for safe, effective, and scalable AI adoption in radiology. While the current landscape is marked by an overwhelming array of AI-enabled point solutions, the future involves running multiple AI models, even for a single use case. DeepHealth's partnership with CARPL.ai addresses this very need by creating a unique environment to dynamically run a combination of models and monitor performance and then continuously optimize the best models for specific tasks," said Sham Sokka, PhD, Chief Operating and Technology Officer, DeepHealth. The partnership will also combine CARPL.ai's AI marketplace and orchestration platform, which offers a simplified process for selecting, implementing, and monitoring third-party FDA-cleared AI models, with DeepHealth's cloud-native operating system, DeepHealth OS, which unifies data across the clinical and operational workflows. These platforms will be integrated and extended to monitor real-world workflows on an ongoing basis. The aim is to enable radiologists to access performant and safe AI interpretation tools deeply integrated in their workflows. "We are very excited to partner with DeepHealth to harness the transformative potential of AI within the radiology care continuum, particularly through workflow automation and clinical assistance. This new AI infrastructure is set to fundamentally redefine radiology by making AI an integral component of the system," said Dr. , CEO of CARPL.ai. "Monitoring AI performance is essential to ensure the reliability and accuracy of AI applications over time, and our technology enables real-time performance monitoring of both their accuracy and consistency for safe and effective use of AI in clinical practice." For more information, visit the DeepHealth (#1340) and CARPL.ai (#5733) booths at the Radiological Society of 2024 Annual Meeting. About is the leading national provider of freestanding, fixed-site diagnostic imaging services in based on the number of locations and annual imaging revenue. has a network of 399 owned and/or operated outpatient imaging centers. RadNet's markets include , , , , , , and . In addition, provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, has a total of over 10,000 employees. For more information, visit http://www.radnet.com. About DeepHealth DeepHealth is a wholly-owned subsidiary of (NASDAQ: RDNT) and serves as the umbrella brand for all companies within segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (i.e., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth and Kheiron breast AI and Quantib prostate and brain AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth's portfolio is a cloud-native operating system - DeepHealth OS - that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth's human-centered, intuitive technology aims to push the boundaries of what's possible in healthcare. https://deephealth.com/ About CARPL.ai CARPL.ai is a vendor-neutral Artificial Intelligence (AI) platform that allows radiologists to access, assess, and integrate radiology AI solutions in their clinical practice. CARPL provides a single user interface, a single data channel, and a single procurement channel for the testing, deployment, and monitoring of AI solutions in clinical radiology workflows. We are the world's largest radiology AI marketplace offering 140+ applications from 60+ AI vendors. For more information, visit https://carpl.ai/. Forward Looking Statement This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements regarding the capabilities of , CARPL.ai, and DeepHealth's informatics, hardware and software product portfolios and the collaboration's impact on radiology practices and healthcare workflow, are expressions of our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements.

RadNet's Wholly-Owned Subsidiary, DeepHealth, to Use CARPL.ai's Platform to Develop a New AI Control System for Clinical AI Performance and Safety By Investing.com

Furthermore, DeepHealth will embed CARPL.ai's cutting-edge AI orchestration capabilities that enable easy selection, implementation, and monitoring of appropriate AI models within DeepHealth's cloud-native operating system, DeepHealth OS. LOS ANGELES and SOMERVILLE, Mass., Dec. 01, 2024 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced a strategic collaboration with CARPL.ai, a leading AI orchestration company that enables radiologists to access, assess, and integrate radiology AI solutions in their workflows. DeepHealth will use CARPL.ai's technology to develop an AI control system that can be commercialized and will be designed to monitor and optimize imaging AI performance for improved clinical outcomes, operational efficiency, and accelerated adoption of AI in radiology. AI monitoring is crucial to ensure reliable, accurate, and unbiased performance. The two companies will collaborate on a new closed-loop AI feedback system that will continually monitor AI model accuracy and relevance in clinical settings. The system will automate the measurement and monitoring of performance and safety metrics such as specificity, sensitivity, data- and model drift. Establishing a robust AI infrastructure with monitoring tools is key for safe, effective, and scalable AI adoption in radiology. While the current landscape is marked by an overwhelming array of AI-enabled point solutions, the future involves running multiple AI models, even for a single use case. DeepHealth's partnership with CARPL.ai addresses this very need by creating a unique environment to dynamically run a combination of models and monitor performance and then continuously optimize the best models for specific tasks, said Sham Sokka, PhD, Chief Operating and Technology Officer, DeepHealth. The partnership will also combine CARPL.ai's AI marketplace and orchestration platform, which offers a simplified process for selecting, implementing, and monitoring third-party FDA-cleared AI models, with DeepHealth's cloud-native operating system, DeepHealth OS, which unifies data across the clinical and operational workflows. These platforms will be integrated and extended to monitor real-world workflows on an ongoing basis. The aim is to enable radiologists to access performant and safe AI interpretation tools deeply integrated in their workflows. We are very excited to partner with DeepHealth to harness the transformative potential of AI within the radiology care continuum, particularly through workflow automation and clinical assistance. This new AI infrastructure is set to fundamentally redefine radiology by making AI an integral component of the system, said Dr. Vidur Mahajan, CEO of CARPL.ai. Monitoring AI performance is essential to ensure the reliability and accuracy of AI applications over time, and our technology enables real-time performance monitoring of both their accuracy and consistency for safe and effective use of AI in clinical practice. For more information, visit the DeepHealth (#1340) and CARPL.ai (#5733) booths at the Radiological Society of North America 2024 Annual Meeting. About RadNet, Inc. RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 399 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 10,000 employees. For more information, visit http://www.radnet.com. About DeepHealth DeepHealth is a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for all companies within RadNet's Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (i.e., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth and Kheiron breast AI and Quantib prostate and brain AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth's portfolio is a cloud-native operating system - DeepHealth OS - that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth's human-centered, intuitive technology aims to push the boundaries of what's possible in healthcare. https://deephealth.com/ About CARPL.ai CARPL.ai is a vendor-neutral Artificial Intelligence (AI) platform that allows radiologists to access, assess, and integrate radiology AI solutions in their clinical practice. CARPL provides a single user interface, a single data channel, and a single procurement channel for the testing, deployment, and monitoring of AI solutions in clinical radiology workflows. We are the world's largest radiology AI marketplace offering 140+ applications from 60+ AI vendors. For more information, visit https://carpl.ai/. Forward Looking Statement This press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements regarding the capabilities of RadNet, CARPL.ai, and DeepHealth's informatics, hardware and software product portfolios and the collaboration's impact on radiology practices and healthcare workflow, are expressions of our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: anticipate, intend, plan, goal, seek, believe, project, estimate, expect, strategy, future, likely, may, should, will and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements.

RadNet's DeepHealth Subsidiary Expands FDA Clearance for SmartMammo™ Solution - RadNet (NASDAQ:RDNT)

SmartMammo™'s AI algorithm now FDA cleared with GE HealthCare's Senographe Pristina™, expanding access to enhanced cancer detection. The clearance enables RadNet's DeepHealth and GE HealthCare collaboration to bring together the SmartMammo and Senographe Pristina solutions and transform breast cancer diagnosis. SOMERVILLE, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a wholly-owned subsidiary of RadNet, Inc. RDNT and a global leader in AI-powered health informatics, has received expanded FDA 510(k) clearance for its innovative mammography software. SmartMammo Dx, the AI algorithm within SmartMammo1, is now FDA-cleared to be compatible with GE HealthCare's Senographe Pristina™ mammography systems. SmartMammo Dx was first cleared in May 2012 in conjunction with HOLOGIC mammography systems, where its performance has also been tested and cleared in patients with unilateral breasts and with breast implants. This newly expanded clearance advances DeepHealth's mission to enhance and expand breast cancer screening programs by broadening system compatibility. "This FDA clearance allows us to expand access to high-quality breast cancer screening to more patients," said Kees Wesdorp, President and CEO of RadNet's Digital Health segment. "By bringing SmartMammo's improved cancer detection to GE HealthCare's mammography systems, more providers can harness the power of AI to help redefine radiology workflows and address key challenges across the imaging value chain, to improve speed, clinical accuracy, operational efficiency, and elevate patient care." SmartMammo Dx is a key component of DeepHealth's comprehensive SmartMammo1 solution, delivering advanced AI-driven tools that empower radiologists to interpret digital breast tomosynthesis (DBT) mammograms with greater precision. The software identifies suspicious soft tissue lesions and calcifications and assigns finding-specific and case-specific suspicion levels with increased diagnostic accuracy. DeepHealth's FDA-cleared breast cancer diagnostic technologies have already supported millions of exams over the last two years with HOLOGIC mammography systems through the Enhanced Breast Cancer Detection (EBCD) program at RadNet. The expanded FDA clearance with GE HealthCare's Senographe Pristina should further accelerate the adoption of AI-powered breast cancer screening at RadNet and with other providers. The FDA clearance underscores DeepHealth and GE HealthCare's shared commitment to advancing patient-centric, interoperable, and scalable imaging solutions. The two companies aim to set new standards in AI-powered breast imaging to help radiologists deliver better care faster. For more information about SmartMammo Dx and its impact on breast cancer screening, visit deephealth.com 1 SmartMammo™ comprises multiple components, including SmartMammo Dx (also known as Saige DX), SmartMammo Density, DeepHealth Viewer, and SmartMammo Assure. DeepHealth Viewer is Manufactured by eRAD and Distributed by DeepHealth. Any claims made about SmartMammo™ may reference claims associated with its individual components. About RadNet, Inc. RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 399 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 10,000 employees. For more information, visit http://www.radnet.com. About DeepHealth DeepHealth is a wholly-owned subsidiary of RadNet, Inc. RDNT and serves as the umbrella brand for all companies within RadNet's Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (i.e., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth and Kheiron breast AI and Quantib prostate and brain AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth's portfolio is a cloud-native operating system - DeepHealth OS - that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth's human-centered, intuitive technology aims to push the boundaries of what's possible in healthcare. https://deephealth.com/ Forward Looking Statement This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements regarding the capabilities of RadNet, GE HealthCare, Hologic and DeepHealth's informatics, hardware and software product portfolios and the collaboration's impact on radiology practices and healthcare workflow, are expressions of our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements. For media inquiries, reach out to: DeepHealth Andra Axente Communications Director Phone: +31 614 440971 Email: andra.axente@deephealth.com RadNet, Inc. Mark Stolper Executive Vice President and Chief Financial Officer 310-445-2800 Market News and Data brought to you by Benzinga APIs

CORRECTION: RadNet's DeepHealth Subsidiary Expands FDA Clearance for SmartMammo™ Solution - RadNet (NASDAQ:RDNT)

SmartMammo™'s AI algorithm now FDA cleared with GE HealthCare's Senographe Pristina™, expanding access to enhanced cancer detection. The clearance enables RadNet's DeepHealth and GE HealthCare collaboration to bring together the SmartMammo and Senographe Pristina solutions and transform breast cancer diagnosis. SOMERVILLE, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Friday, November 29th by RadNet, Inc. RDNT, please note that in the third sentence of the first paragraph, the year that SmartMammo Dx was first cleared should be 2021, not 2012. The corrected release follows: DeepHealth, Inc., a wholly-owned subsidiary of RadNet, Inc. RDNT and a global leader in AI-powered health informatics, has received expanded FDA 510(k) clearance for its innovative mammography software. SmartMammo Dx, the AI algorithm within SmartMammo1, is now FDA-cleared to be compatible with GE HealthCare's Senographe Pristina™ mammography systems. SmartMammo Dx was first cleared in May 2021 in conjunction with HOLOGIC mammography systems, where its performance has also been tested and cleared in patients with unilateral breasts and with breast implants. This newly expanded clearance advances DeepHealth's mission to enhance and expand breast cancer screening programs by broadening system compatibility. "This FDA clearance allows us to expand access to high-quality breast cancer screening to more patients," said Kees Wesdorp, President and CEO of RadNet's Digital Health segment. "By bringing SmartMammo's improved cancer detection to GE HealthCare's mammography systems, more providers can harness the power of AI to help redefine radiology workflows and address key challenges across the imaging value chain, to improve speed, clinical accuracy, operational efficiency, and elevate patient care." SmartMammo Dx is a key component of DeepHealth's comprehensive SmartMammo1 solution, delivering advanced AI-driven tools that empower radiologists to interpret digital breast tomosynthesis (DBT) mammograms with greater precision. The software identifies suspicious soft tissue lesions and calcifications and assigns finding-specific and case-specific suspicion levels with increased diagnostic accuracy. DeepHealth's FDA-cleared breast cancer diagnostic technologies have already supported millions of exams over the last two years with HOLOGIC mammography systems through the Enhanced Breast Cancer Detection (EBCD) program at RadNet. The expanded FDA clearance with GE HealthCare's Senographe Pristina should further accelerate the adoption of AI-powered breast cancer screening at RadNet and with other providers. The FDA clearance underscores DeepHealth and GE HealthCare's shared commitment to advancing patient-centric, interoperable, and scalable imaging solutions. The two companies aim to set new standards in AI-powered breast imaging to help radiologists deliver better care faster. For more information about SmartMammo Dx and its impact on breast cancer screening, visit deephealth.com 1 SmartMammo™ comprises multiple components, including SmartMammo Dx (also known as Saige DX), SmartMammo Density, DeepHealth Viewer, and SmartMammo Assure. DeepHealth Viewer is Manufactured by eRAD and Distributed by DeepHealth. Any claims made about SmartMammo™ may reference claims associated with its individual components. About RadNet, Inc. RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 399 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 10,000 employees. For more information, visit http://www.radnet.com. About DeepHealth DeepHealth is a wholly-owned subsidiary of RadNet, Inc. RDNT and serves as the umbrella brand for all companies within RadNet's Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (i.e., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth and Kheiron breast AI and Quantib prostate and brain AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth's portfolio is a cloud-native operating system - DeepHealth OS - that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth's human-centered, intuitive technology aims to push the boundaries of what's possible in healthcare. https://deephealth.com/ Forward Looking Statement This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements regarding the capabilities of RadNet, GE HealthCare, Hologic and DeepHealth's informatics, hardware and software product portfolios and the collaboration's impact on radiology practices and healthcare workflow, are expressions of our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements. For media inquiries, reach out to: DeepHealth Andra Axente Communications Director Phone: +31 614 440971 Email: andra.axente@deephealth.com RadNet, Inc. Mark Stolper Executive Vice President and Chief Financial Officer 310-445-2800 Market News and Data brought to you by Benzinga APIs

CORRECTION: RadNet's DeepHealth Subsidiary Expands FDA Clearance for SmartMammo™ Solution By Investing.com

SOMERVILLE, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Friday, November 29th by RadNet, Inc. (NASDAQ: RDNT), please note that in the third sentence of the first paragraph, the year that SmartMammo Dx was first cleared should be 2021, not 2012. The corrected release follows: DeepHealth, Inc., a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and a global leader in AI-powered health informatics, has received expanded FDA 510(k) clearance for its innovative mammography software. SmartMammo Dx, the AI algorithm within SmartMammo1, is now FDA-cleared to be compatible with GE HealthCare's Senographe Pristina™ mammography systems. SmartMammo Dx was first cleared in May 2021 in conjunction with HOLOGIC mammography systems, where its performance has also been tested and cleared in patients with unilateral breasts and with breast implants. This newly expanded clearance advances DeepHealth's mission to enhance and expand breast cancer screening programs by broadening system compatibility. This FDA clearance allows us to expand access to high-quality breast cancer screening to more patients, said Kees Wesdorp, President and CEO of RadNet's Digital Health segment. By bringing SmartMammo's improved cancer detection to GE HealthCare's mammography systems, more providers can harness the power of AI to help redefine radiology workflows and address key challenges across the imaging value chain, to improve speed, clinical accuracy, operational efficiency, and elevate patient care. SmartMammo Dx is a key component of DeepHealth's comprehensive SmartMammo1 solution, delivering advanced AI-driven tools that empower radiologists to interpret digital breast tomosynthesis (DBT) mammograms with greater precision. The software identifies suspicious soft tissue lesions and calcifications and assigns finding-specific and case-specific suspicion levels with increased diagnostic accuracy. DeepHealth's FDA-cleared breast cancer diagnostic technologies have already supported millions of exams over the last two years with HOLOGIC mammography systems through the Enhanced Breast Cancer Detection (EBCD) program at RadNet. The expanded FDA clearance with GE HealthCare's Senographe Pristina should further accelerate the adoption of AI-powered breast cancer screening at RadNet and with other providers. The FDA clearance underscores DeepHealth and GE HealthCare's shared commitment to advancing patient-centric, interoperable, and scalable imaging solutions. The two companies aim to set new standards in AI-powered breast imaging to help radiologists deliver better care faster. For more information about SmartMammo Dx and its impact on breast cancer screening, visit deephealth.com 1 SmartMammo™ comprises multiple components, including SmartMammo Dx (also known as Saige DX), SmartMammo Density, DeepHealth Viewer, and SmartMammo Assure. DeepHealth Viewer is Manufactured by eRAD and Distributed by DeepHealth. Any claims made about SmartMammo™ may reference claims associated with its individual components. About RadNet, Inc. RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 399 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 10,000 employees. For more information, visit http://www.radnet.com. About DeepHealth DeepHealth is a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for all companies within RadNet's Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (i.e., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth and Kheiron breast AI and Quantib prostate and brain AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth's portfolio is a cloud-native operating system - DeepHealth OS - that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth's human-centered, intuitive technology aims to push the boundaries of what's possible in healthcare. https://deephealth.com/ Forward Looking Statement This press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements regarding the capabilities of RadNet, GE HealthCare, Hologic (NASDAQ:HOLX) and DeepHealth's informatics, hardware and software product portfolios and the collaboration's impact on radiology practices and healthcare workflow, are expressions of our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: anticipate, intend, plan, goal, seek, believe, project, estimate, expect, strategy, future, likely, may, should, will and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements.

RadNet's DeepHealth Subsidiary Expands FDA Clearance for SmartMammo™ Solution

, (GLOBE NEWSWIRE) -- , a wholly-owned subsidiary of (NASDAQ: RDNT) and a global leader in AI-powered health informatics, has received expanded FDA 510(k) clearance for its innovative mammography software. SmartMammo Dx, the AI algorithm within SmartMammo, is now FDA-cleared to be compatible with GE HealthCare's Senographe Pristina™ mammography systems. SmartMammo Dx was first cleared in in conjunction with HOLOGIC mammography systems, where its performance has also been tested and cleared in patients with unilateral breasts and with breast implants. This newly expanded clearance advances DeepHealth's mission to enhance and expand breast cancer screening programs by broadening system compatibility. "This FDA clearance allows us to expand access to high-quality breast cancer screening to more patients," said , President and CEO of RadNet's segment. "By bringing SmartMammo's improved cancer detection to GE HealthCare's mammography systems, more providers can harness the power of AI to help redefine radiology workflows and address key challenges across the imaging value chain, to improve speed, clinical accuracy, operational efficiency, and elevate patient care." SmartMammo Dx is a key component of DeepHealth's comprehensive SmartMammo solution, delivering advanced AI-driven tools that empower radiologists to interpret digital breast tomosynthesis (DBT) mammograms with greater precision. The software identifies suspicious soft tissue lesions and calcifications and assigns finding-specific and case-specific suspicion levels with increased diagnostic accuracy. DeepHealth's FDA-cleared breast cancer diagnostic technologies have already supported millions of exams over the last two years with HOLOGIC mammography systems through the Enhanced Breast Cancer Detection (EBCD) program at . The expanded FDA clearance with GE HealthCare's Senographe Pristina should further accelerate the adoption of AI-powered breast cancer screening at and with other providers. The FDA clearance underscores DeepHealth and GE HealthCare's shared commitment to advancing patient-centric, interoperable, and scalable imaging solutions. The two companies aim to set new standards in AI-powered breast imaging to help radiologists deliver better care faster. For more information about SmartMammo Dx and its impact on breast cancer screening, visit deephealth.com SmartMammo™ comprises multiple components, including SmartMammo Dx (also known as Saige DX), SmartMammo Density, DeepHealth Viewer, and SmartMammo Assure. DeepHealth Viewer is Manufactured by eRAD and Distributed by DeepHealth. Any claims made about SmartMammo™ may reference claims associated with its individual components. About is the leading national provider of freestanding, fixed-site diagnostic imaging services in based on the number of locations and annual imaging revenue. has a network of 399 owned and/or operated outpatient imaging centers. RadNet's markets include , , , , , , and . In addition, provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, has a total of over 10,000 employees. For more information, visit http://www.radnet.com. About DeepHealth DeepHealth is a wholly-owned subsidiary of (NASDAQ: RDNT) and serves as the umbrella brand for all companies within segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (i.e., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth and Kheiron breast AI and Quantib prostate and brain AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth's portfolio is a cloud-native operating system - DeepHealth OS - that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth's human-centered, intuitive technology aims to push the boundaries of what's possible in healthcare. https://deephealth.com/ Forward Looking Statement This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements regarding the capabilities of , , Hologic and DeepHealth's informatics, hardware and software product portfolios and the collaboration's impact on radiology practices and healthcare workflow, are expressions of our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements.

RadNet's DeepHealth Subsidiary Expands FDA Clearance for SmartMammo™ Solution By Investing.com

SOMERVILLE, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and a global leader in AI-powered health informatics, has received expanded FDA 510(k) clearance for its innovative mammography software. SmartMammo Dx, the AI algorithm within SmartMammo, is now FDA-cleared to be compatible with GE HealthCare's Senographe Pristina™ mammography systems. SmartMammo Dx was first cleared in May 2012 in conjunction with HOLOGIC mammography systems, where its performance has also been tested and cleared in patients with unilateral breasts and with breast implants. This newly expanded clearance advances DeepHealth's mission to enhance and expand breast cancer screening programs by broadening system compatibility. This FDA clearance allows us to expand access to high-quality breast cancer screening to more patients, said Kees Wesdorp, President and CEO of RadNet's Digital Health segment. By bringing SmartMammo's improved cancer detection to GE HealthCare's mammography systems, more providers can harness the power of AI to help redefine radiology workflows and address key challenges across the imaging value chain, to improve speed, clinical accuracy, operational efficiency, and elevate patient care. SmartMammo Dx is a key component of DeepHealth's comprehensive SmartMammo solution, delivering advanced AI-driven tools that empower radiologists to interpret digital breast tomosynthesis (DBT) mammograms with greater precision. The software identifies suspicious soft tissue lesions and calcifications and assigns finding-specific and case-specific suspicion levels with increased diagnostic accuracy. DeepHealth's FDA-cleared breast cancer diagnostic technologies have already supported millions of exams over the last two years with HOLOGIC mammography systems through the Enhanced Breast Cancer Detection (EBCD) program at RadNet. The expanded FDA clearance with GE HealthCare's Senographe Pristina should further accelerate the adoption of AI-powered breast cancer screening at RadNet and with other providers. The FDA clearance underscores DeepHealth and GE HealthCare's shared commitment to advancing patient-centric, interoperable, and scalable imaging solutions. The two companies aim to set new standards in AI-powered breast imaging to help radiologists deliver better care faster. For more information about SmartMammo Dx and its impact on breast cancer screening, visit deephealth.com SmartMammo™ comprises multiple components, including SmartMammo Dx (also known as Saige DX), SmartMammo Density, DeepHealth Viewer, and SmartMammo Assure. DeepHealth Viewer is Manufactured by eRAD and Distributed by DeepHealth. Any claims made about SmartMammo™ may reference claims associated with its individual components. About RadNet, Inc. RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 399 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 10,000 employees. For more information, visit http://www.radnet.com. About DeepHealth DeepHealth is a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for all companies within RadNet's Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (i.e., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth and Kheiron breast AI and Quantib prostate and brain AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth's portfolio is a cloud-native operating system - DeepHealth OS - that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth's human-centered, intuitive technology aims to push the boundaries of what's possible in healthcare. https://deephealth.com/ Forward Looking Statement This press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements regarding the capabilities of RadNet, GE HealthCare, Hologic (NASDAQ:HOLX) and DeepHealth's informatics, hardware and software product portfolios and the collaboration's impact on radiology practices and healthcare workflow, are expressions of our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: anticipate, intend, plan, goal, seek, believe, project, estimate, expect, strategy, future, likely, may, should, will and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements.